TALENT- neoadj T-DXd in HR+/HER2-low #bcsm
RCB0/1:
🔹 T-DXd alone: 16%
🔹 T-DXd + anastrozole: 17%
🔹 T-DXd → TC chemo: 17%
*no pCRs w/out 8 cycles
Despite high ORR ~66%, pCR LOW! We know w/ HR+ we don't get high pCRs rates, but still disappointing
#ESMO26 #ESMOAmbassadors
1014 浏览 · 11 赞 · 8 转发 · 2 回复
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.org- Rebecca Shatsky, MD@Dr_RShatsky
@ErikaHamilton9 Why do we have trials that include luminal A breast cancer patients getting chemo?? 😕#Breastcancer
- Erika Hamilton, MD, FASCO@ErikaHamilton9
https://www.esmo.org/insights-by-esmo/all-news/low-rates-of-pathological-complete-response-reported-with-trastuzumab-deruxtecan-in-early-breast-cancer #ESMO26 #ESMOAmbassadors
来源：Erika Hamilton, MD, FASCO · x.com